The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.
Bertrand Tombal
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Medivation
Michael Borre
No relevant relationships to disclose
Per Rathenborg
No relevant relationships to disclose
Patrick Werbrouck
No relevant relationships to disclose
Axel Heidenreich
Honoraria - Astellas Pharma
Peter Iversen
Honoraria - Astellas Pharma
Edwina S. Baskin-Bey
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
De Phung
Employment or Leadership Position - Astellas Pharma
Matthew Raymond Smith
Honoraria - Astellas Pharma; Medivation